Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration
Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration
复制标题
DOI：
10.1097/iae.0b013e31816b316e
复制
发表时间：
2008-05-01
影响因子：
3.3
通讯作者：
Mittra, Robert A.
中科院分区：
文献类型：
--
作者：
Smith, Bradley T.;Dhalla, Mandeep S.;Mittra, Robert A.
目的：报道玻璃体内注射贝伐单抗联合维替泊芬光动力疗法（PDT）治疗年龄相关性黄斑变性（AMD）患者脉络膜新生血管（CNV）的结果。研究设计和参与者：干预性、连续性、回顾性病例系列，包括40例新诊断的继发于AMD的近中心凹或中心凹下CNV患者的40只眼。对玻璃体内注射1.25 mg贝伐珠单抗，随后在2周内进行PDT治疗的患者的图表进行了审查。主要结果的措施是视力稳定（定义为没有变化或视力的增益）和需要retreatment.Results：33（83%）的40只眼视力稳定。视力平均提高1.73行。26只眼（65%）仅需要单次玻璃体内注射贝伐单抗联合PDT。随访12个月的23只眼中，17只眼（74%）视力稳定，9只眼（40%）视力提高（平均1.22 Snellen线）。在12个月随访时，11只眼（48%）仅需要单次联合治疗即可解决CNV。仅随访6个月的17只眼中，有15只（88%）只需要单一联合治疗。有没有并发症，如眼内炎，葡萄膜炎，或高眼压症。结论：这些研究结果表明，用玻璃体内注射贝伐单抗和PDT治疗的眼睛需要没有到最小数量的再治疗，有稳定的视力，即使在12个月的后续。进一步的研究与大型对照试验是必要的，以概述适当的治疗模式，联合治疗。
Purpose: To report the outcome for eyes treated with intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).Study Design and Participants: Interventional, consecutive, retrospective case series including 40 eyes of 40 patients with newly diagnosed juxtafoveal or subfoveal CNV secondary to AMD.Methods: The charts of patients treated with a 1.25-mg intravitreal injection of bevacizumab followed by PDT within a 2-week period were reviewed. Main outcome measures were visual acuity stabilization (defined as no change or a gain in visual acuity) and need for retreatment.Results: Thirty-three (83%) of 40 eyes had stabilization of visual acuity. Mean improvement in visual acuity was 1.73 lines. Twenty-six eyes (65%) required only a single intravitreal injection of bevacizumab combined with PDT. Of the 23 eyes with 12 months of follow-up, 17 (74%) had stabilization of visual acuity, while 9 (40%) had improvement in visual acuity (mean, 1.22 Snellen lines). Eleven eyes (48%) required only a single combined treatment for CNV resolution at the 12-month follow-up. Fifteen (88%) of 17 eyes with only 6 months of follow-up required only a single combined treatment. There were no complications such as endophthalmitis, uveitis, or ocular hypertension.Conclusion: These findings suggest that eyes treated with both intravitreal injection of bevacizumab and PDT require none to a minimal number of re-treatments to have stabilization of vision, even at 12 months of follow-up. Further investigation with large controlled trials is warranted to outline the appropriate treatment paradigm for combination therapy.